










































Thrombolytic treatment for elderly patients
Citation for published version:
Elder, AT & Fox, KA 1992, 'Thrombolytic treatment for elderly patients' BMJ, vol 305, no. 6858, pp. 846-7.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
Each new study builds on its predecessors, providing new
information, which aids the fine tuning of treatment. In the
case of hypertension in elderly patients this includes the blood
pressure levels at which to treat, the target blood pressure,
upper age limits, how to manage other cardiovascular risk
factors, and the use of newer drugs such as calcium antago-
nists and angiotensin converting enzyme inhibitors.
For combined systolic and diastolic hypertension the trial
data suggest that treatment should be started at pressures
above 160/90 mm Hg, and the target should be to lower both
systolic and diastolic pressures below these levels. Similarly,
in isolated systolic hypertension 160 mm Hg should be taken
as the threshold, though recommendations regarding isolated
systolic hypertension must be tentative pending confirmation
from the Syst-Eur trial. Although a cautious approach to
implementing the results of recent landmark studies may be
wise, inaction cannot be justified in the face of the substantial
body of information pointing towards the need to treat raised
blood pressure in elderly patients.
One is led inevitably to the conclusion of Fotherby and
colleagues that authoritative, clear guidelines for managing
this common disorder are needed and that such guidelines
should be revised regularly. Who should be responsible? The
British Hypertension Society has produced useful guidelines
on treating mild hypertension and is currently reviewing
them. Perhaps it should set itself the task of doing this both
for hypertension in general and hypertension in elderly
patients in particular, reviewing its guidelines biennially.
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Thrombolytic treatment for elderly patients
Age is not a contraindication
The risk of having a myocardial infarction and of dying as a
result increases with age: about 80% of fatal myocardial
infarctions in Britain occur in patients over 65.' A 75 year old
with an acute myocardial infarction is seven times more likely
to die in hospital than a patient aged 50, and mortality
remains twice that of younger patients after discharge.2
Why is the mortality so much greater in elderly people?
Conditions such as heart failure, angina, diabetes, and
hypertension coexist more frequently, and all contribute to a
poorer outcome.2 So does increased age itself' and possibly the
altered cardiac and systemic responses to myocardial infarc-
tion described in elderly patients.3 Another reason, however,
is that they are often treated differently from younger
patients.34
Several studies have shown that thrombolytic treatment
reduces mortality and morbidity after acute myocardial
infarction59 and, although not designed to assess the efficacy
or safety of treatment in elderly patients, their results agree:
thrombolytic agents produce the greatest reductions in
absolute mortality in those at highest risk of death-
particularly older patients. For example, in the second
international study of infarct survival (ISIS-2)- combined
treatment with streptokinase and aspirin saved 10 lives for
every 1000 patients treated aged under 60 but 47 lives for
every 1000 patients over 70.7
Such benefit from thrombolysis depends on prompt admin-
istration, ideally within six hours of the onset of symptoms.
Compared with other patients with myocardial infarction,
elderly patients are more likely to present late, be difficult to
diagnose, and have absolute contraindications to throm-
bolysis. Some must therefore be excluded from treatment,' "
and the prescription rate of thrombolytic agents in elderly
patients should not be expected to equal that in younger
patients. Evidence exists, however, that some older patients
are left untreated for less clearly justifiable reasons.
A recent survey of coronary care units in Britain suggested
that 40% set an upper age limit for the use of thrombolysis and
20% excluded patients from coronary care, where throm-
bolysis is usually given, on the grounds of age alone. 12 Even in
coronary care units not operating a formal age policy,
thrombolysis is used less than in younger patients, often for
poorly defined reasons. Experience in North America seems
similar: one study showed that a patient aged 75 with no
contraindications to thrombolysis had only half the chance of
a similar patient aged 40 of receiving treatment.4 Perhaps
audit, which has already been used to identify and minimise
inappropriate underuse, can improve matters.'3
Why is the use of thrombolysis apparently restricted on the
grounds of age? Cost effectiveness is at least as good as in
younger patients.'4'5 Apprehension regarding the risk of
haemorrhagic complications persists and" may discourage
some doctors from giving thrombolytic drugs to older
patients. The risk of stroke at or around the time of
myocardial infarction increases with age-to 1-% in patients
aged over 75 who are untreated and to 1-7% in those of similar
age who receive thrombolysis. 6 This level of risk- six strokes
per 1000 patients treated in this age group -is, however, far
from that required to negate the overall benefits ofthromboly-
tic drugs on mortality and morbidity in elderly patients.
Other concerns may exist. How might thrombolysis affect
other important end points such as symptoms, function, and
dependence? Will the early benefits on mortality be offset by a
greater requirement for relatively high risk interventional
treatment? Current research suggests not. '7
Ultimately, decisions regarding the appropriate use of
thrombolysis in older patients can become rational only if
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studies are analysed not only by patients' ages but also
according to their functional state and the presence of co-
existent disease. At present, age is too frequently used as a
convenient but inaccurate proxy for other, less easily
measured indices of likely benefit and possible risk.
Clear reasons exist for treating elderly patients with
thrombolytic agents: lives can be saved and myocardial
function improved. We should ensure that the reasons for
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Treating psoriasis with calcipotriol
Early studies are promising
Psoriasis is a chronic and distressing disease of uncertain
aetiology which can be hard to treat. There is no cure. Topical
measures such as tars and dithranol are of limited effect and
acceptability, and steroids, although addictive to both
patients and prescribers, have their well known hazards. Oral
agents all have side effects and limitations.' An obvious gap
therefore exists in the armoury of available treatments.
Sunlight and ultraviolet B radiation work in some cases of
psoriasis, and their benefits have been attributed to increased
production of cholecalciferol in the skin.2 Treatment of
osteoporosis with 1a-cholecalciferol showed improvement in
coincidental psoriasis, and one study found that chole-
calciferol helped patients with psoriasis.3 A larger study could
not confirm this, possibly because the dose was too small.4
The problem is that giving a large enough dose to overcome
the resistance to the antiproliferative activity of 1,25-
dihydroxycholecalciferol in patients with psoriasis5 carries the
risks of hypercalcaemia and calciuria: hence the search for
analogues of cholecalciferol for topical use.
Calcipotriol is one such drug.6 Early studies have shown
that it is at least as effective as betamethasone,7 ifnot more so8;
and it is superior to short term dithranol.9 Patients seem to
like it, and it can be used for up to a year. Further experience
of its use has been encouraging, and official approval has
followed.'0 A paper in this week's journal extends its use to
pustular psoriasis, which can be very difficult to manage and
has an appreciable mortality (p 868). "
The benefits ofcalcipotriol are ease and tolerability ofuse-
the cream is colourless and invisible on the skin and does not
stain. The lack of colour and smell appeals to patients, many
ofwhom have had bad experiences with tars and dithranol. It
clears chronic plaques at a varying rate, and the benefits
usually appear in two to three weeks. Its use on the face is not
recommended as it produces soreness in most patients and
perioral dermatitis in about 4%.9 There is little experience of
its use on flexures; some patients may not tolerate it. Many
patients experience irritation and soreness in both chronic
plaques and the normal skin around them, which increases
with time. My own experience suggests that discomfort and
poor tolerance of calcipotriol occur mainly in three groups;
fair skinned patients who burn easily in the sun; patients who
have recently had courses of etretinate, which increases skin
sensitivity; and patients who have been treated with strong
corticosteroids long term.
Although calcipotriol's makers recommend its use for only
six weeks followed by a gap, there are reports of safe use for a
year.'0 The discomfort settles quickly when calcipotriol is
withdrawn, and it can usually be reintroduced later without
problem. Patients need to be careful about exposure to the
sun, but so do many patients with active psoriasis. The
maximum recommended amount is 100 g a week to minimise
the theoretical risk of hypercalcaemia. Calcipotriol is rapidly
inactivated, however, and has a much smaller effect on
calcium metabolism than 1,25-dihydroxycholecalciferol."2'3
Extensive or unstable disease could alter the absorption of
calcipotriol, so it is interesting that up to 300 g has been given
in 10 days without problem." These doses were given to sick
patients in hospital who were being carefully monitored. The
theoretical possibility of resorption of bone has not been
confirmed clinically.8 Long term studies may show problems,
but as yet the prospects are optimistic and calcipotriol is
already widely accepted.
Calcipotriol's mode ofaction is still unclear. Proliferation of
epidermal keratinocytes (one of the hallmarks of psoriasis) is
reduced and terminal differentiation increased.8 Inflamma-
tion is reduced as is the activity of ornithine decarboxylase.
This enzyme suppresses proliferating T lymphocytes,' prob-
ably by inhibiting the production of interleukin-2. This
immunological action suggests that calcipotriol may be useful
in other conditions, such as contact dermatitis, skin cancers,
and pityriasis rubra pilaris. Trials are also under way in
Darier's disease and the ichthyoses. We will hear more of
calcipotriol.
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